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Gaining strategic advantage
Analytical chemistry enjoyed a revolution in instrumen-
tal techniques during the 1960s and 1970s. This, in turn,
stimulated new developments of simple laboratory auto-
mation led by improved analytical instruments, auto-
samplers and chromatographic integratcs. During the
1980s, new generations of powerful laboratory automa-
tion emerged; primarily laboratory information systems
and laboratory robotics for sample automation.
In most applications, today’s analytical techniques are
capable ofproducing the required quality data. The next
step is to maintain, and even raise, these standards while
increasing analytical capacity. Trace analysis continues
to demand greater sensitivity to measure ever-lower trace
levels. Meeting this requires continuing technology
improvements in sample preparation, separations tech-
niques and analytical measurements.
Superior productivity
Superior productivity requires earning the greatest
economic value from resources; people, time and capital.
Improving productivity is valuable today, but will
become critical to survival in the future and business will
continue to demand more and more from their laboratory
investment. Not only must today’s laboratories improve
internal productivity, they must stimulate productivity
throughout their company by contributing quality,
timely information for critical business decisions.
In manufacturing, for example, errors in quality data might
lead to shipping unacceptable products or rejecting
acceptable products. Either condition initiates an ever
more costly set of potential consequences, including:
(a) Demotivating dedicated staff.
(b) Sorting good from bad.
(c) Rework.
(d) Scrap.
(e) Late customer deliveries.
C/) Customer complaints.
(g) Cancelled orders.
(h) Lost customers.
(i) Product recalls.
(]’) Law suits.
If the problems continue undiscovered or unresolved, the
financial and emotional costs increase exponentially; in
large companies, for example, lost customers, product
recalls and law suits typically cost millions of dollars.
Whilst it would be desirable to have error-flee data to
verify each critical step in manufacturing processes, it is
too expensive to test every step thoughout the entire
process. Instead, good data should be generated at key
steps and introduce sufficient controls to quickly identify
and solve potential problems. This leads to additional
guiding principles:
(i) For effective analytical support, introduce analysis
and testing prior to high value-added steps.
(ii) Turn results around quickly. Since data is generated
for critical business decisions, its value decreases
rapidly over time.
Truly successful businesses require excellent technology,
superior product quality and world-class customer
service to achieve market leadership. This requires
outstanding contributions by skilled, motivated people,
thus high value-added people are essential to high value-
added organizations.
Experience clearly shows:
(1) The value of good, timely data far exceeds the cost of
determining it.
(2) The cost of bad data far exceeds any savings from
inadequate analytical support.
(3) Problem resolution usually demands more data.
This paper was read at the International Symposium on Laboratory
Automation and Robotics (October 1992, Boston, USA).
For example, rnodern adhesives are used in high value-
added manufacturing such as the assembly of critical
aircraft structures. It is vital to test the adhesive’s
characteristics prior to assembling valuable parts into a
permanent structure.
In research and product development, analytical errors often
cause large opportunity costs. That is the lost time of
valuable people and the delay in reaching conclusions,
either successful or unsuccessful. These opportunity costs
are never recovered and they continue to grow until the
error is detected, replaced with valid data and a new
direction is set. In the pharmaceutical industry, for
example, a successful, new ethical drug should achieve
annual sales of at least $250 M. In this example,
misdirected development which delays product commer-
cialization costs the profit contribution from $1 million
revenue per day of delay.
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The changing role of laboratory management
As modern analytical chemistry emerged, laboratory
managers needed to be technical experts in order to
establish, staff and direct laboratories capable of quality
analytical results. Managers spent their time training
people in new technologies, acquiring modern instrumen-
tation and developing operating procedures. Labora-
tories were centralized to gain access to the limited
expertise in new analytical technologies and expensive
instruments.
In the past, laboratory managers responded to daily
demands for analytical support. Today’s laboratory
managers are proactive. They seek better ways to apply
technology and resources to achieve business objectives.
The companies listed in figure 1, for example, have made
major commitments to laboratory automation- includ-
ing more powerful computers, new instrumentation and
robotics and workstations for sample automation. Their
experience demonstrates compelling business reasons for
their investment and the significant benefits actually
achieved.
Bristol-Myers Squibb, Pharmaceutical Research
Institute (2)
Glaxo, Inc., Research Institute
Hershey Foods Corporation, Corporate Analytical
Johnson & Johnson, R. W. Johnson Pharmaceutical
Research Institute
Miles, Inc., Consumer Healthcare Division
Pfizer, Inc., Central Research Analytical
Developement
Sandoz Pharmaceuticals, Sandoz Research Institute
Shell Development Company, Analytical Chemistry
R&D
SmithKline Beecham Clinical Laboratories
Warner Lambert Company, Parke-Davis Research
Division
WMI Environment Monitoring Laboratories, Inc.
Figure 1. Laboratory automation strategic case histories.
Effective investing in laboratory automation
Many automation projects require significant resource
investments. These investments must bejustified in terms
of business value and superiority over alternative invest-
ments. Typical accounting practices approach automa-
tion justification simply as a direct substitute for people
performing the same task. Less quantitative benefits,
such as more timely decisions, better quality, more
effective people, are often excluded from the justification.
Enlightened managements recognize the limitations of
traditional finanical justifications and are introducing
new approaches. Judy Lewent, Vice President and Chief
Financial Officer of Merck & Co., Inc., has described
these new principles.
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People talk about how short-termism is driven out of
the fact that financial people force discounted cash-flow
ROI [Return on Investment] down the throats of
everybody, and these high hurdle rates, this high cost of
capital, is what stultifies investment. I just come back
and say if you really understand the business, and
you’re a partner with the operating members of your
business, then you marry the right kind of financial
parameters to the business opportunities, and be an aid
to the process, a strategic ally as opposed to policeman
{1].
The insights and experiences of the executives who
contributed their case histories, identify the objectives
leading to their strategic success with laboratory automa-
tion (figure 2). The complete case histories are summar-
ized in Appendix A. Highlighted below are brief state-
ments illustrating the justification and benefits.
Affordable capacity for significantly higher sample
loads and more complex testing per sample.
’Just-in-time analysis’ for faster new product introduc-
tion, timely correction of quality problems and
enhanced customer service.
Improved precision, documentation and defensible
audit trails.
Significantly reduce analysis cost in order to routinely
gather all the data necessary to solve problems quickly
rather than wait for more data.
Transfer valid, analytical methods to multiple sites-
worldwide.
Improve motivation, reduce turnover and enhance
effectiveness of valuable, scarce people.
Utilize laboratory space more effectively.
Figure 2. Business objectivesfor laboratory automation
Affordable capacity
From 1985 through 1988, the Bristol-Myers Squibb
Pharmaceutical Research Institute, increased the
number of assays by 42% per year while the staffing
increased by 12% per year. With 1985’s productivity, it
would have taken 115 more people, along with space and
instruments, to perform 1988’s assays. This dramatic
productivity increase was accomplished with improved
instrumentation, computers and laboratory robotics (see
Appendix A, reference 1).
Bristol-Myers Squibb’s Metabolism and Pharmaco-
kinetics Scientific Operations was able to use the added
capacity of their initial laboratory robotics system to
perform about 8000 assays in-house that would have had
to be subcontracted- realizing $400 000 in cost savings.
Longer term, they are developing new levels oflaboratory
automation to double their capacity to 500 000 assays per
year (see Appendix A, reference 2).
SmithKline Beecham Clinical Laboratories (SBCL)
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rapidly increasing demands for testing, together with
higher costs and lower prices. To meet this challenge,
their competitive strategy for the year 2000 requires
investment for improved employee utilization, more
efficient specimen processing, improved quality and
enhanced service. They invested in laboratory robotics
for drugs of abuse confirmation testing after new
developments demonstrated a four..-fold throughput
increase compared to earlier robotic approaches (see
Appendix A, reference 10).
The Parke-Davis Pharmaceutical Research Division of
Warner Lambert has reported a 20% annual increase in
the number of stability samples and a doubling of the
number of tests per sample. Laboratory automation is a
key element of their stategy to meet these accelerating
needs (see Appendix A, reference 11).
At Sandoz Research Institute, automated techniques
increased their number of screening assays from 300 in
1987 to over 11 000 in 1992 (see Appendix A, reference 8).
Automated Dissolution Testing at Johnson & Johnson’s
R. W. Johnson Pharmaceutical Research Institute has
saved over $1 500 000 since 1985 (see Appendix A,
reference 5).
WMI Environment Monitoring Laboratories, Inc. tests
ground-water samples from landfills owned and operated
by Waste Management, Inc. During four years of use,
their automated Chemical Oxygen Demand (COD)
assays have returned approximately 600% on their
investment (see Appendix A, reference 12).
Just-in-time analysis
’Timeliness of results is our challenge for the 90s. All the
return on investment justifications to purchase a robot
cannot dojustice to the need for timeliness Timeliness
in the form of robotics has replaced cost as a competitive
advantage to a food company’ (Hershey Foods Corpor-
ation- Appendix A, reference 4).
Miles’s goal is to achieve ’just-in-time release’ ofproducts
immediately following manufacture and packaging. To
succeed, Miles needs more analytical data and faster
sample turnaround than ever before (Miles, Inc., Con-
sumer Healthcare Division Appendix A, reference 6).
The Glaxo, Inc., Research Institute reported that about
two years ago, management wanted to accelerate clinical
trials for an important new drug. Rather than subcon-
tract these assays, Glaxo’s bioanalytical staff requested
the opportunity to demonstate even faster turnaround by
performing the assays in-house with laboratory robotics.
Using a fully automated system, these bioanalytical
assays were completed in two weeks (see Appendix A,
reference 3).
’Successful robotic automation of key elements of the
analytical process will lead to more timely and high
quality decision-making_ rather than a deferral of
decision-making awaiting more data... Improved
quality of regulatory submissions will lead to faster
approvals of new products. Timely in-process infor-
mation will shorten the development cycle’ (Warner
Lambert, Appendix A, reference 11).
Improved precision, documentation and defensible
audit trails
Improved data quality and documentation are some of
the most widely reported benefits of laboratory automa-
tion. A dramatic drop in cost per assay enable Squibb to
provide more data with improved quality and better
documentation. This investment provides Bristol-Myers
Squibb with a strategic advantage in the competitive
drug development business (see Appendix A, reference
1).
Significantly reduce analysis cost
In many quality control situations, the cost of analytical
data limits the amount of routine analysis. Typically,
laboratories must generate additonal data in order to
determine the cause ofspecific problems. Using two, fully
automated content uniformity systems, Miles staff rou-
tinely generates sufficient data, in virtual real time, to
correct problems quickly and ensure quality production
(see Appendix A, reference 6).
Transfer valid analytical methods to multiple sites
Hershey uses laboratory robotic automation in their
central analytical laboratories and has transferred the
technology to the main plant laboratories and in-plant
mini-labs (see Appendix A, reference 4).
These results triggered a new confidence in laboratory
robotics technology. Today, it is the approach of choice.
US laboratories are training Glaxo people, from around
the world, on the effective use of the technology (see
Appendix A, reference 3).
Improve motivation, reduce turnover and enhance
effectiveness of people
’When a robot is used,, one can reasonably expect to see
dramatic improvements in safety, productivity and
precision. Even more important is the improvement in
quality of life for employees, since robots do best those
kinds ofjobs which are seldom interesting or challenging
for humans’ (Shell Development Company- Appendix
A, reference 9).
’This dramatic success generated even greater commit-
ment and additional strategic benefits, including...
energizing existing staff and attracting new people as
work became less routine and more challenging’ (Glaxo,
Inc.- Appendix A, reference 9).
’The purpose of robotics is to gain throughput, relieve
staff of repetitive tasks, permit them to use their greatest
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tool, their brain, and most important of all, to yield
routinely precise and accurate results in a timely manner’
(Hershey Foods Corporation- Appendix A, reference 4).
Adopting automated drug-screening techniques at San-
doz Research Institute, dramatically enhanced the job
content for bench scientists (see table 1):
Table 1. Drug screening at Sandoz Research Institute.
Bench scientist activity
Analysis and data management
New assay development and personal
skill development
1987 1991
54.0% 10.0%
46-0% 90.0%
See Appendix A, reference 8.
Utilize laboratory space more efficiently
Today, virtually all laboratories are space limited and
valuable laboratory space is now a strategic resource. The
reasons for this include:
(1) It is expensive and must be added in large incre-
ments- people can be added incrementally, but
space must be added in economical units. Even with
sufficient land, the smallest practical new laboratory
construction would be 30 000 to .50 000 square feet.
This requires an investment of between $6 and
$10 M. The relocation costs need to be added.
(2) Long lead time: a decision to construct new labora-
tory space nust be made 18 to 24 months, or more,
before it is needed.
(3) Requires extensive management time: successful
laboratory expansions require management time to
ensure that plans match strategic needs, plan lay-
outs, redeploy people and instrumentation and
negotiate conflict generated by the expansion.
If the average cost oflaboratory space is $150 to $200 per
square foot, the ’real’ cost ofusable bench space will be in
the range of $750 to $1500 per linear foot.
Justifying laboratory automation: calculating direct
cost savings
The decision to invest in laboratory automation should be
based meeting the stategy and financial needs of the
business. Today’s executives must place a value on
intangibles and make them part of a business justifica-
tion. Begin justification with the guidelines highlighted in
figure 3.
Whether saving direct people cost is the prirnary
justification or a side benefit, it’s important to make valid
calculations of the projected savings.
The first step is to determine average hours saved per unit
of work. To do this, detc.rmine the actual effort currently
expended, not the theoretical or ideal goal. Next, project
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Determine the real business for automating this
naethod or methods.
Quantify the economic value of these benefits.
Short-term labour savings are typically a reduction of
investment- rather than the primary benefit.
If significantly lower ’cost of analysis is the primary
benefit, calculate savings on the projected sample
loads. Compare savings to actual experience not ideal
models.
If this is new technology for you, consider a ’facilitat-
ing investment’ by amortizing the learning and start-
up costs over potential projects.
Figure 3. Systematic approach tojustifying laboratory automation.
the effort required to perform the work using the proposed
automated method. The difference becomes the man-
hours saved per unit of work. Finally, convert this to
savings per week using the amount ofwork performed, or
projected, each week.
Calculating direct cost savings: example
Step l. Calculating real cost. Example: annual cost of senior
lechnician
Direct cost elements Annual cost
Annual salary- no overtime $30 000
Direct benefits 10 000
Medical, life, FICA, disability,
workers compensation, unemploy-
ment, retirement, 401K, Profit
sharing
Space & utilities 200 sq. ft.
Communication, travel, training
Other
Total direct cost
2000
1500
1500
$45 ooo
Note: Senior staff may have higher salaries and benefits
are more costly in many companies. Costs do not include,
supervision, administrative support overhead or profit.
Step 2. Analysis of days available to perform job assignment
Days
260
Category
Total working days per year
Less, equivalent days not available
Vacation 13
Sick 5
Holidays 10
Training 5
Travel 3
Breaks & distractions at hour per day 30
Administrative- neetings, supervision, reports 14
Total not available 80
Days not available to perIbrm job assignment 180
Note: This is 70% of total time, which considered
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Step 3. Summary
Available hours to perform thejob assignment is 180 days
x 8 hours per day 1440 hours.
The cost per hour actually performing thejob assignment
is $45 000 annual cost divided by 1440 hours available
per year $31.00 per hour.
The annual savings from saving hour per day
performing the job assignment is 250 hours per year at
$31.00 per hour $7500.
Therefore, by saving hour per day:
A $7500 investment will be recovered in year.
A $15 000 investment will be recovered in 2 years.
In many organizations, the annual cost per person is
much higher than this example and fewer days are
available to perform the job assignment. Under these
conditions, paybacks can be far faster than shown above.
Conclusion
The strategic challenges caused by world-wide compe-
tition and regulation continue to increase. People and
time are our most .precious resources.
Modern laboratories must become a catalyst and role
model stimulating greater productivity throughout their
organizations. Laboratory managers must grow as busi-
ness executives bridging the laboratory to strategy.
Laboratory automation technology has demonstrated its
ability to significantly enhance productivity in the
laboratory and beyond.
Reference
1. Wall Street Journal (30 June 1992), p A 17.
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Reference 1 (October 1991)
Bristol-Myers Squibb: Glenn A. Brewer, Executive Director, Worldwide
Analytical Systems, Bristol-Myers Squibb, Pharmaceutical Research
Institute, New Brunswick, NJ, USA
In 1984, Squibb (now Bristol-Myers Squibb) Research
Institute anticipated rapidly increasing needs for analytic
assays to support their drug development programme.
Increasing demand for content uniformity, dosage form
stability and body fluid assays was stimulated by multiple
forces; including, accelerated research and development,
internal research demands for more data and changing
regulatory requirements.
Squibb managers and scientists determined that only a
strategic commitment to sample preparation automation,
advanced analytical techniques and powerful data man-
agement would meet their needs.
They convinced senior management, organized for auto-
mation, established a critical mass of talent and equip-
ment and developed methods to take full advantage ofthe
new technology. This total commitment delivered
impressive results.
1985 1986 1987 1988
Laboratory staff 79 87 105 110
Total routine assays 35 177 51 702 85476 101 256
Assays per person 445 594 814 921
During this period, staffing increased 12% per year while
total routine assays increased 42% per year. In order to
perform 1988’s assays at 1985’s productivity, Squibb
would have had to add 115 more people along with
sufficient laboratory space and instrumentaion.
The dramatic drop in cost per assay enabled Squibb to
provide more data with improved quality and better
documentation. This investment provides Bristol-Myers
Squibb with a strategic advantage in the competitive
drug development business.
Bristol-Myers Squibb Case History 1.
Reference 2 (October 1992)
Bristol-Myers Squibb: Raymond H. Farmen, Director, Metabolism and
Phar,nacokinetics Scientific Operations, Bristol-Myers Squibb Pharma-
ceutical Research Institute, Syracuse, NY, USA
Bristol-Myers Squibb’s Pharmaceutical Research Insti-
tute has extensive laboratory operatiolas in Syracuse,
New York and New Brunswick, New Jersey. Their
Metabolism and Pharmacokinetics (MAP) Scientific
Operations are responsible for bioanalytical assays
radiochemical synthesis and computer data systems in
support of pre-clinical and clinical studies.
Several years ago, MAP Scientific Operations anticipated
dramatic increases in the number ofbioanalytical studies
required for new drug approval. To meet this challenge,
they pioneered the use of new instrumentation,
computers, laboratory robotics and automation work-
stations for bioanaltyical assays. By most standards they
are highly automated today, and yet, they are planning
even more powerful laboratory automation capability to
meet the expected work load three to five years in the
future. Today MAP Scientific Operations perform about
300 000 assays per year in their laboratories and in
contract laboratories. Their goal is to develop capacity to
perform 500 000 assays annually.
The following example highlights the effective use ofboth
robotic systems and automation workstations at their
Syracuse, New York laboratories to support Bristol-
Myers Squibb’s NDA for a new antidepressant, nefazo-
done. They developed a liquid/liquid extraction pro-
cedure for three metabolites. Later, a second liquid/
liquid extraction method was developed for a fourth
metabolite, thus requiring two liquid/liquid assays per
sample. These liquid/liquid extractions were performed
by a Zymate robotic system. To reduce the number of
assays, they developed a manual solid phase extraction
(SPE) method capable of measuring all metabolites in a
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single assay. This SPE method was transferred to a
BenchMate Workstation to handle the growing sample
load. Since then, the laboratory has added a second
BenchMate Workstation and a second Zymate robotic
system capable ofboth liquid/liquid and SPE extractions.
The added capacity provided by laboratory automation
permitted internal running ofthe increased sample load-
by existing staff. The initial robotic system generated
these cost containment savings during 1990 and 1991.
Looking forward, MAP Scientific Operations plan to
further increase capacity for even more bioanalytical
assays; generated by expanded new product development
regulatory requirements for more data and the routine
assay of more standards made possible by automation.
Their goal is to gain a 10-fold increase in assays per
analyst by investing in laboratory instruments,
computers and automation- supported by a highly
skilled staff of automation siSentists. In addition, they
expect to decrease the typical study turn-around time
from six to eight weeks down to one to two weeks. By
substantially reducing assay cost and study turn-around
time, this centralized laboratory will attract bioanalytical
work from Bristol-Myers Squibb’s laboratories around
the world.
MAP Scientific Operations recognize the technology and
management challenges ahead. They are also energized
by the exciting career development opportunities being
created.
Cost containment from robotic automation
Samples analysed during 1990 and 1991 with robotics:
18 306 samples
Estimated sample capacity using manual methods:
10 800 samples
Samples assayed in-house that would have required
contract laboratory service: 8266 samples
Typical contract laboratory fee: $50 per sample
Contract laboratory savings (1990 and 1991): (8226
samples) ($50 per sample) $411 300
Bristol-Myers Squibb Case History 2.
Reference 3 (October 1991)
Glaxo, Inc. Research Institute: Julie J. Tomlinson, Robotics Laboratory
Manager, Clinical Pharmaceutics, Research Triangle Park, NC, USA
Glaxo, a leading multinational pharmaceutical company,
has major research and development laboratories in the
UK and the USA, with smaller laboratories around the
world. Rapid new product development is a vital element
ofGalxo’s business strategy. Bioanalytical assays for drug
metabolism studies are a critical factor in Glaxo’s
development process.
Glaxo was an early user of laboratory robotics for drug
metabolism with limited success, and senior management
was cautious about full commitment to this new tech-
nology. Up to 70% of their bioanalytical assays were
performed by contract laboratories.
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About two years ago, management wanted to accelerate
the clinical trials for an important new drug. Rather than
subcontract these assays, Glaxo’s bioanalytical assay staff
requested the opportunity to demonstrate even faster
turnaround by performing the assays in-house with
laboratory robotics. Using a fully automated system,
these bioanalytical assays were completed in two weeks.
These results triggered a new confidence in laboratory
technology. Today, it is the approach of choice. Seven
automated methods are performed routinely on four
robotic systems. Only 30% of their bioanalytical assays
are now subcontracted. And, the US laboratories are
training Glaxo people, from around the world,, on the
effective use of this technology.
This dramatic success generated even greater commit-
ment and additional strategic benefits, including:
(1) Effective methods transfer throughout Glaxo’s
worldwide laboratories.
(2) Energizing existing staffand attracting new people as
work became less routine and more challenging.
(3) Improved analytical precision particularly through
use of gravimetric techniques.
(4) Lower cost of analysis to meet the analytical
demands of increasing regulation.
(5) Greater safety for people working with human
biological samples.
Reference 4 (October 1991)
Hershey Foods Corporation: Robert A. Martin, Jr., Sr. Manager,
Corporate Analytical Laboratories, Hershey, PA, USA
Hershey Foods Corporation is a leading food company
with one of the most advanced analytical capabilities in
the food industry. Increasing demands for quality,
labelling and safety assessment make today’s food
laboratory a strategic resource.
Robert Martin presented the following ideas at the Food
Labs ’91 Conference:
’Hershey uses laboratory robotic automation on their
central analytical laboratories and have transferred the
technology to the main plant laboratories and in-plant
mini-labs. Their automation goal is not replacing
people. Rather... The purpose of robotics is to gain
throughput, relieve staff of repetitive tasks, permit
them to use their greatest tool, their brain, and most
important of all, to yield routinely precise and accurate
results in a timely manner.
A major challenge to the food laboratory in the 1990s
will be to incorporate the equivalent of just-in-time
delivery of inventory and manufacture of finished
goods. This is just-in-time results This is where
robotics earns its keep; it frees staff to persue new
technologies and react to one-off emergency situations
to produce timely results.
Timeliness ofresults is our challenge for the 90s. All the
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cannot do justice to the need for timeliness
TIMELINESS in the form of robotics has replaced
COST as a competitive advantage to a food company’.
In a recent communication, Dr Martin summarized his
thoughts: ’Laboratory robotics is notjust a good idea, it is
a necessary reality to address the demands placed on the
laboratory of the 1990s’.
Reference 5 (October 1992)
Johnson & Johnson: Irwin Gibbs, Director, Pharmaceutical Develop-
ment, R. W. Johnson Pharmaceutical Research Institute, Spring House,
PA, USA
The Pharmaceutical Development department at John-
son & Johnson’s R. W. Johnson Research Institute
provides solid dosage form dissolution testing services for
many of J&J’s pharmaceutical development projects.
They support formulation development, clinical study
supplies, process development and process scaleup. The
number ofdissolution sample batches remained relatively
constant during the 1980s, but began increasing in 1990.
The pharmaceutical development staff anticipated the
increasing work demands and, in 1985, installed their
initial laboratory robotics system to automate dissolution
testing.
As they gained experience, a growing percentage of their
dissolution testing was converted from manual to auto-
mated processing. By 1991, 90% of all dissolution testing
was performed by three automated systems. During 1991,
this saved 52% in man-days leading to financial savings
over $500 000. From 1985 through 1991, the cumulative
savings earned by automated dissolution testing exceeded
$1 500 000.
Their three systems are virtually identical and are
capable of running a wide range of dissolution assays.
This automation not only increases assay capacity, but
also automatically generates easily retrieved documen-
tation for future reference.
j&j’s approach to automated dissolution testing encour-
aged the rapid development and validation of automated
methods and companion manual methods. The com-
panion methods ensure a validated fall back alternative
and also provide regulatory agencies with a valid method
which can be performed by a non-automated laboratory.
Irwin Gibbs, Director of Pharmaceutical Development,
states; ’The success of laboratory robotics in automating
dissolution testing has lead the way towards future efforts
to automate other laboratory testing in Pharmaceutical
Development at the R. W. Johnson Pharmaceutical
Research Institute.
Reference 6 (October 1991)
Miles Inc., Consumer Healthcare Division: Bernd C. Schade, Director of
Quality Assurance, Elkhart, IN, USA
Miles Consumer Healthcare Division, a large manufac-
turer of over-the-counter pharmaceutical products, has
installed fully automated content uniformity testing for
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Figure 4.
its Alka-Seltzer family of antacid and cold-relief tablets.
Miles produces over 10 M Alka-Seltzer tablets each day
using seven formulations.
Miles’ goal is to achieve ’just-in-time release’ ofproducts
immediately following manufacture and packaging. To
succeed, Miles ,needs more analytical data and faster
sample turnaround than ever before. In essence, Miles is
approaching traditional, final product quality-control at
a process control challenge.
In many quality control situations, the cost of analytical
data limits the amount of routine analysis. Typically,
laboratories must generate additonal data in order to
determine the cause of specific problems. Further in high
volume production, the time delay in obtaining sufficient
data leads to continuing production of large quantities of
potentially unsatisfactory product.
Today, Miles has two fully automated content uniformity
systems for Alka-Seltzer quality assurance. The dual
capability ensures adequate testing capacity, rapid
sample turnaround and back-up reliability. Miles’s staff
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routinely generates sufficient data, in virtual real time, to
correct problems quickly and ensure quality production.
Their automation investment significantly reduced cost
per analysis and, beyond this, they gained greater
production productivity through lower scrap, reduced
sorting of finished products and more rapid inventory
turnover.
Alka Seltzer is a registered trademark of Miles Inc.
Reference 7 (October 1992)
Pfizer, Inc.: Central Research Division, James E. Curley, Assistant
Director, Analytical Research & Development, Groton, CT, USA
Pfizer scientists in Analytical Research & Development
pioneered in the use of laboratory robotics beginning in
1983. They have applied robotic automation to tablet
dissolution testing, tablet assays and dosed feed analysis.
Senior management recognized the growing need for
analytical support and the importance of relieving skilled
scientists from routine work. They identified laboratory
robotics as a new technology with the potential to meet
these needs.
Tablet dissolution testing was selected for automation
because regulatory trends require dissolution rate specifi-
cations for tablets and capsules. Early testing was based
upon the premise cited in the USP that a single-time
point determination at 45 minutes would assure thera-
peutic acceptability if the product was 75% dissolved. As
the technology has become more extensively used,
dissolution rate testing has taken on an additional role of
assuring that manufacturing processes remain in control.
Today, dissolution rate testing is included in a series of
tests that ’fingerprint’ the quality of a dosage form.
During drug development, comprehensive dissolution
studies are preformed for multiple dosage formulations to
profile dissolution rate and stability. For immediate
release tablets, routine dissolution assays continue to be
single point, but sample timing is selected to provide the
most information about that specific drug formulation.
The more demanding uses for dissolution data, require
even greater control over assay parameters such as media
composition, temperature and dissolved gas. This, in
turn, requries more powerful automation to measure and
control these parameters as well as perform the actual
test.
Pfizer has standardized their automated dissoluton
approach such that their robotic systems become virtual
workstations. Early attempts to have sample submitters
directly interface with the systems were unsuccessful so
Analytical Research provides skilled operators to set up
and run samples.
Dosed feed assays for safety assessment and metabolism
studies, are also successful laboratory robotics appli-
cations. Early in the development of a drug candidate,
there may not be sufficient time to develop an automated
analytical method to support safety studies. The goal,
however, is to use a robotic system by the time the drug
candidate is in long-term safety studies.
Tablet assay automation, however, has not met Pfizer’s
expectations. They desire a standardized, robust and
compact automated workstation. Efficient laboratory
space utilization has become a strategic factor in Pfizer’s
laboratory automation programmes.
Reference 8 (October 1992)
Sandoz Pharmaceuticals, Sandoz Research Institute: David B. Wein-
stein, Director Dennis S. France, Senior Scientist, Atheroscleroris and
Vascular Biology Research, East Hanover, NJ, USA
Sandoz Pharmaceuticals is a leading, multi-national
developer and producer of pharmaceutical and health-
care producs. In his keynote presentation at the 1991
International Symposium on Laboratory Automation
and Robotics, David Weinstein described how robotics
accelerated their drug discovery research and stimulated
a more creative scientific environment.
Dr Weinstein described a new environment in which
laboratory robotics plays a key role: ’The role of the
research director who is the product champion is to blend
together the research personnel components with the
creative environment provided by mangement in order to
create the successful and stable integration of robotics
into the early stages of drug discovery... At Sandoz
Research Institute, we have created an opportunity for
enterprising biologists to develop a drug discovery
programme that is heavily based on robotic microplate
management systems as analysis tools. This programme
was accomplished with minimum amounts of funding
and a staff of no more than two over a two-year period’.
Compounds Screened
40O
Figure 5.
Assays per
Compound Screened
20
15
10
5
0
1987 1988 1989 1990 1991 1992
Total Assays
2000
0000
8000
$000
4000
2000
0
1987 1988 1989 lSSO 1991 lSS2
3OF. H. Zenie Superior productivity in the laboratory and beyond
There are typically three stages in the rational drug
discovery process:
(1) Determine the biological site or mechanism of action
to target.
(2) Develop in vitro and in vivo test models, which can
discriminate between compounds with effectively
alter the selected biological target.
(3) Assign large numbers ofmedical chemists to provide
rational concepts toward design of complicated
chemical molecules which may achieve the desired
biological response.
Sandoz have realized a dramatic increase in screening
assays from their manual assay capability in 1987
through installation ofthe firs’t robotic system in 1988 and
a second system in 1990. These assays are from complex
in vivo screens which increased from 100 compounds
tested in 1988 to well over 500 in 1992. More importantly,
automation enabled them to increase the number of
assays per compound from three in 1988 to 20 in 1992.
The total number of assays, therefore, increased 35 fold
from 300 in 1987 to over 11 000 in 1992.
At Sandoz, laboratory robotics provides a powerful tool
to automate laboratory screening and, in doing so, frees
up valuable time ofskilled scientists. This is illustrated by
the change in bench scientist activity at Sandoz between
1987 and 1991.
Bench scientist activity
Analysis and data managment
New assay development
Staff meetings
Scientific meetings
Management functions, training
and job enrichment
1987 1991
54-0% 10"0%
32"0% 40"0%
10-0% 20"0%
4"0% 15"0%
0"0% 15"0%
While significantly more bioanalytical work is performed,
the scientific staff is able to perform high value-added
functions, develop new scientific knowledge and partici-
pate in managment functions.
Dr Weinstein has explained that this rational approach is
often balanced by the traditional pharmaceutical pro-
gramme of’random-screening’ of natural sources such as
bacterial and fungal broths, plant extracts and natural
herbal remedies. To be most productive, random-
screening requires effective screening mechanisms
followed by laboratory screening of large numbers of
candidate samples.
Large pharmaceutical companies typically have com-
pound libraries containing tens of thousands of pure
compounds, most of which are in sufficient quantity
routine for screening. In addition to the complex in vivo
screens, therefore, Sandoz also performs random, in vitro
assays for enzyme and receptor targets. Typically, in
random screening programmes, the rate limiting steps
are compound weighing dissolving.
Recently, the Atherosclerosis and Vascular Biology
department applied laboratory automation to give San-
doz scientists improved access to the Sandoz Research
Institute compound library. Using a BenchMate robotic
workstation they:
(a) Automatically tared 200 test tubes.
(b) Manually transferred a non-quantitative amount of
compound.
(c) Automatically weighed tubes and calculated net
compound weight.
(d) Automatically dispensed the appropriate amount of
water and DMSO to yield a final concentration of 1"0
mg/ml and 50% DMSO.
(e) Automatically downloaded compound weights to an
Oracle database which updated the compound
inventory.
Based on weighing and dissolving 6000 compounds, they
averaged 60 compounds per person-hour- a 10-fold
improvement over prior manual methods.
Future automation plans at Sandoz include automating
radioactive assays and high speed, automated pipetting
to make replicate samples from the compound library.
Reference 9 (October 1991)
Shell Development Company: Glenn L. Taylor, Director, Analytical
Chemistry R&D, Houston TX, USA
In his keynote presentation at the 1990 International
Symposium on Laboratory Automation and Robotics.
Glenn Taylor highlighted the strategic role of laboratory
robotics at Shell Development Company: ’Analytical
chemistry is being revolutionized by new capabilities
conferred by the computer. At the same time, business
has to face a new set of environmental and regulatory
demands plus new competing pressures. Concurrent with
this is a culture stressing quality and continual improve-
ment, and in-depth fulfillment ofcustomer requirements.
In analytical chemistry, this translates to a need for more
accurate, more rapid and more cost-effective analytical
service’.
There are many forms of successful laboratory automa-
tion: ’Robots are probably the most complex of these
approaches, and should be used only when the other
forms of automation will not suffice. However, when a
robot is used, one can reasonably expect to see dramatic
improvements in safety, productivity and precision. Even
more important is the improvement in quality of life for
employees, since robots do best those kinds ofjobs which
are seldom interesting or challenging for humans’.
Specifically, Shell reports:
(1) The first robot at Shell has handled over 40 000
samples since 1984. It paid for itself within four
months and requires no more than about one hour of
setup and maintenance per day.
(2) Payback periods have been six months or less for
several applications.
(3) Some environmental applications have been success-
fully duplicated at operating locations.
(4) Robotic applications have helped minimize worker
exposure to hazardous chemicals and reagents.
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Shell expects the number of quantitative analyses in
which robots are involved, one way or another, to
increase from approximately 20% of the analyses in 1990
to over 50% by 1995. In conclusion, our experience at
Shell with robotics has been a very positive one. In every
case, we can identify benefits that were not foreseen in the
original justification of the robotic equipment.
Reference 10 (October 1991)
SmithKline Beecham Clinical Laboratories: David O’Bryan, Vice
President, Production Support Services, King of Prussia, PA, USA
SmithKline Beecham Clinical Laboratories (SBCL) is
the leading independent clinical testing laboratory in the
United States. Analysing samples is their business.
The clinical testing industry is facing strategic opportun-
ities and challenges.
(1) Clinical testing will increase due to our aging
population.
(2) Government and third party reimbursements are
decreasing.
(3) Large, efficient laboratories are likely to be the
primary providerof sophisticated tests in the future.
(4) The supply of trained laboratory staff is rapidly
falling behind industry needs while salaries and
benefits are increasing.
(5) Regulatory requirements continue to increase.
SBCL believes that larger central laboratories can be
more cost effective and afford the technology skills and
automation investment necessary to meet these chal-
lenges. Their competitive strategy for the year 2000,
includes:
(a) Improve employee utilization.
(b) Participate and assist in laboratory consolidation.
(c) Invest in capital technology to improve quality and
enhance service.
(d) Improve the entire testing process from specimen
acquisition and ordering to results entry and filing.
A growing business segment for SBCL is drugs of abuse
testing. Following initial screening, positive screens are
confirmed by GC/MS. GC/MS confirmation testing
requires extensive sample pre-treatment prior to analysis;
and commercially available clinical analysers are
unsuited to these pre-treatment procedures. To satisfy
their needs, SBCL determined that automated sample
prep was necessary and that it must meet NIDA
regulations, deliver near term savings and become a
platform for long term competitive advantage. While
laboratory robotics had demonstrated capability to
perform quality sample prep for drugs ofabuse confirma-
tion, existing capabilities fell short ofSBCL’s throughput
requirements. Detailed discussions between SBCL and
Zymark led to a new approach. Utilizing Zymark’s new
XP Robot, advanced control techniques and indepen-
dently functioning peripherals, it met all requirements.
Zymark and SBCL collaborated on this development
and, today, two systems are installed in SBCL
laboratories.
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Reference 11 (October 1991)
Warner Lambert Company: Mahdi B. Fawzi, Vice President ofProduct
Development, Parke-Davis Pharmaceutical Research Division Morris
Plains, NJ, USA
In his keynote presentation at the 1990 International
Symposium on Laboratory Automation and Robotics, Dr
Fawzi described how laboratory automation is a strategic
resource for meeting the regulatory and competitive
demands of the pharmaceutical industry: ’The com-
plexity of new drugs and delivery systems will increase,
and the characterization required for pharmaceutical
products of the future will be far greater than for
conventional drugs and delivery systems. Recruitment
and retention of pharmaceutical product development
scientists requires enrichment of thejob. In our industry,
the first company to gain approval and market new
products, usually captures the largest market share’.
At Warner Lambert:
(1) The number of samples requiring analysis increased
20% per year from 1988 to 1990.
(2) The number of tests per stability sample more than
doubled between 1985 and 1990.
(3) The cost for domestic stability testing of samples
requiring HPLC analysis range from $400 000 to
$600 000.
’Successful robotic automation of key elements of the
analytical process will lead to more timely and higher
quality decision-making rather than deferral of decision-
making awaiting more data. Improved quality of infor-
mation and prompt turnaround are expected to improve
decision making... Improved quality of regulatory
submissions will lead to faster approvals ofnew products.
Timely in-process information will shorten the develop-
ment cycle. Robotic automation has the necessary
flexiblity to turn this vision into reality’.
Reference 12 (October 1992)
WMI Environmental Monitoring Laboratories, Inc.: Deborah C.
Hockman, President, Geneva, IL, USA
WMI Environmental Monitoring Laboratories, Inc.
(WMI-EML) is a wholly owned company of Waste
Management, Inc. a worldwide leader in environmental
services. WMI-EML tests ground-waste samples utiliz-
ing state-of-the-art facilities and equipment, including
robotic automation, to meet EPA requirements. The
samples are obtained from landfills and other facilities
owned and/or operated by Waste Management.
While many analytical laboratories operate as corporate
cost centres, WMI-EML operates as a profit centre and
must be competitive with independent testing labora-
tories in terms of price, service and quality. Waste
Management created WMI-EML as a centralized
groundwater testing laboratory supporting their landfills
throughout the US and Canada. The large number of
samples (nearly 200 000 in 1991), in similar matrices,F. H. Zenie Superior productivity in the laboratory and beyond
made the laboratories ideal candidates for robotic
laboratory automation.
As a business, WMI-EML evaluates capital investments
by calculating the payback period required to recover the
investment. For automation projects, the fixed cost
includes system cost, set-up cost and applicable over-
head. The variable cost per sample includes operator
cost, overhead, chemicals and miscellaneous. The break-
even point is then the number of samples where the total
fixed plus variable costs equal the revenue.
The initial laboratory robot installed at WMI-EML was
applied to Chemical Oxygen Demand (COD) assays.
COD assays were selected as the first robotic application
because of the rapid payback potential. For that appli-
cation, the break-even point was determined to be about
4000 samples which represented about eight months
work. During its four years of use, the total return on
investment is approximately 600%.
The accuracy of the robotic system compared to manual
methods, shown opposite, was evaluated in a blind study
using samples from the Wisconsin Department ofNatural
Resources. Data in mg/1.
Average
Recovery
Robotic method Manual method
112 94
105 91
109 94
109 93
98% 84%
The three robotic systems currently in use at WMI-EML
have delivered:
(1) Rapid financial payback
(2) Equal or better data quality compared to manual
procedures.
(3) Legally defensible documentation.
(4) Rapid sample turn-around-time. For example, the
COD system can process 120 tests, operating unat-
tended, during a 24-hour period.
(5) Improved staff utilization, including the transfer of
human effort to innovation instead ofmundane tasks.
Dr Hockman concluded that: ’Laboratory robotics is a
cost effective, automation tool as essential to the
modern laboratory as a LMS or autosampler on an
instrument’.
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